Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
25
MRK Quote, Financials, Valuation and Earnings
Last price:
$98.24
Seasonality move
:
1.97%
Day range:
$97.90 - $99.68
52-week range:
$94.48 - $134.63
Dividend yield:
3.18%
P/E ratio:
20.56x
P/S ratio:
3.95x
P/B ratio:
5.57x
Volume:
29.2M
Avg. volume:
13.5M
1-year change:
-6.94%
Market cap:
$248B
Revenue:
$60.1B
EPS (TTM):
$4.77
Analysts' Opinion
-
Consensus RatingMerck & has received a consensus rating of Buy. The company's average rating is a Buy based on 16 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $128.73, Merck & has an estimated upside of 31.29% from its current price of $98.05.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $100.00 representing -1.99% downside risk from its current price of $98.05.
Fair Value
-
According to the consensus of 23 analysts, Merck & has 31.29% upside to fair value with a price target of $128.73 per share.
MRK vs. S&P 500
-
Over the past 5 trading days, Merck & has underperformed the S&P 500 by -1.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Merck & does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Merck & has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Merck & reported revenues of $16.7B.
Earnings Growth
-
Merck & earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Merck & reported earnings per share of $1.24.
Enterprise value:
271.6B
EV / Invested capital:
3.28x
Price / LTM sales:
3.95x
EV / EBIT:
18.14x
EV / Revenue:
4.30x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
18.30x
Price / Operating cash flow:
16.80x
Enterprise value / EBITDA:
14.12x
Gross Profit (TTM):
$47.9B
Return On Assets:
11.06%
Net Income Margin (TTM):
19.23%
Return On Equity:
29.26%
Return On Invested Capital:
15.67%
Operating Margin:
23.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $59B | $59.3B | $63.2B | $16B | $16.7B | |
| Gross Profit | $41.6B | $43.2B | $47.9B | $11.7B | $12.6B | |
| Operating Income | $18.5B | $8.2B | $14.2B | $5.9B | $4B | |
| EBITDA | $21.6B | $12.3B | $19.2B | $7B | $5.6B | |
| Diluted EPS | $6.01 | $1.80 | $4.77 | $1.86 | $1.24 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.6B | $31.1B | $33.6B | $32B | $40.4B | |
| Total Assets | $89.8B | $93.5B | $107.1B | $106.7B | $117.5B | |
| Current Liabilities | $20.4B | $23.7B | $23B | $23.1B | $29.6B | |
| Total Liabilities | $60.5B | $57.6B | $62.6B | $65.4B | $73B | |
| Total Equity | $29.3B | $35.9B | $44.5B | $41.3B | $44.6B | |
| Total Debt | $28.7B | $26.4B | $30.4B | $34.9B | $38.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $19.7B | $17.2B | $18.3B | $7.7B | $9.3B | |
| Cash From Investing | -$15.3B | -$15.9B | -$6.2B | -$334M | -$3.8B | |
| Cash From Financing | -$2.4B | -$4.1B | -$6.3B | -$4.3B | -$2.4B | |
| Free Cash Flow | $15.2B | $13.2B | $14.8B | $6.8B | $8.5B | |
MRK
Sector
Market Cap
$248B
$43.9M
Price % of 52-Week High
72.83%
45.73%
Dividend Yield
3.18%
0%
Shareholder Yield
3.05%
-0.74%
1-Year Price Total Return
-6.94%
-29.11%
Beta (5-Year)
0.393
0.772
Dividend yield:
3.18%
Annualized payout:
$2.96
Payout ratio:
63.72%
Growth streak:
13 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$99.88
200-day SMA
Sell
Level
$117.99
Bollinger Bands (100)
Sell
Level
101.59 - 115.45
Chaikin Money Flow
Buy
Level
746.8M
20-day SMA
Sell
Level
$101.05
Relative Strength Index (RSI14)
Sell
Level
40.50
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-96.8268
50-day SMA
Sell
Level
$102.36
MACD (12, 26)
Sell
Level
-0.84
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
794.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8362)
Sell
CA Score
(Annual)
Level (-0.6378)
Buy
Beneish M-Score
(Annual)
Level (-3.0002)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (19.6764)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Stock Forecast FAQ
In the current month, MRK has received 16 Buy ratings 7 Hold ratings, and 0 Sell ratings. The MRK average analyst price target in the past 3 months is $128.73.
-
Where Will Merck & Stock Be In 1 Year?
According to analysts, the consensus estimate is that Merck & share price will rise to $128.73 per share over the next 12 months.
-
What Do Analysts Say About Merck &?
Analysts are divided on their view about Merck & share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Merck & is a Sell and believe this share price will drop from its current level to $100.00.
-
What Is Merck &'s Price Target?
The price target for Merck & over the next 1-year time period is forecast to be $128.73 according to 23 Wall Street analysts, 16 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is MRK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Merck & is a Buy. 16 of 23 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MRK?
You can purchase shares of Merck & via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Merck & shares.
-
What Is The Merck & Share Price Today?
Merck & was last trading at $98.24 per share. This represents the most recent stock quote for Merck &. Yesterday, Merck & closed at $98.05 per share.
-
How To Buy Merck & Stock Online?
In order to purchase Merck & stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 2.79% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.8% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.31% over the past day.
